Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease
NCT07556718Phase 2Recruiting
- Sponsor
- University of Michigan
- Start
- Jun 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing Amitriptyline with Placebo (2 arms). Primary endpoint: Serious Adverse Events at 24 weeks. Started Jun 2026; status: recruiting.
02
Drugs
amitriptyline
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07556718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07556718.